title: Cardiac transplantation after mechanical circulatory support: a Canadian perspective.
abstract: BACKGROUND
  To assess the relative efficacy of cardiac transplantation after mechanical circulatory support with a variety of support systems, we analyzed our consecutive series of patients who had and did not have mechanical support before transplantation.
  
  
  METHODS
  A review of 209 patients undergoing cardiac transplantation from 1984 to May 1995 was performed. Group 1 consisted of 110 patients who were maintained on oral medications while awaiting transplantation, and group 2 consisted of 60 patients who required intravenous inotropic support. Group 3 included 39 patients who had transplantation after mechanical circulatory support for cardiogenic shock. The indication for device implantation was acute onset of cardiogenic shock in 38 patients and deterioration while awaiting transplantation in 1 patient. The support systems were an intraaortic balloon pump in 13 (subgroup 3A), a ventricular assist device in 7 (subgroup 3B), and a total artificial heart in 19 patients (subgroup 3C).
  
  
  RESULTS
  After transplantation, infection was more common in group 3 (56%) than in group 1 (28%) or group 2 (32%) (p = 0.005). Survival to discharge was lower for group 3 (71.7%) than for group 1 (90.9%) or 2 (88.3%) (p = 0.009). For mechanically supported patients, survival to discharge was 84.6% in subgroup 3A, 71.4% in subgroup 3B, and 63.1% in subgroup 3C (p = not significant).
  
  
  CONCLUSIONS
  Transplantation after mechanical support offers acceptable results in this group of patients for whom the only alternative is certain death. Patient selection and perioperative management remain the challenge to improving these results.
authors.affiliation: Division of Surgery, University of Ottawa Heart Institute, Ottawa Civic Hospital, Ontario, Canada.
authors.forename: R G
authors.initials: RG
authors.lastname: Masters
authors.forename: P J
authors.initials: PJ
authors.lastname: Hendry
authors.forename: R A
authors.initials: RA
authors.lastname: Davies
authors.forename: S
authors.initials: S
authors.lastname: Smith
authors.forename: C
authors.initials: C
authors.lastname: Struthers
authors.forename: V M
authors.initials: VM
authors.lastname: Walley
authors.forename: J P
authors.initials: JP
authors.lastname: Veinot
authors.forename: T V
authors.initials: TV
authors.lastname: Mussivand
authors.forename: W J
authors.initials: WJ
authors.lastname: Keon
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001243:Assisted Circulation / Q000009:adverse effects; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003327:Coronary Disease / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology; D016027:Heart Transplantation / Q000009:adverse effects; D006354:Heart, Artificial; D006353:Heart-Assist Devices; D006801:Humans; D007275:Injections, Intravenous; D007423:Intra-Aortic Balloon Pumping / Q000295:instrumentation; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009864:Ontario; D010351:Patient Discharge; D011446:Prospective Studies; D012770:Shock, Cardiogenic / Q000601:surgery; D013530:Surgical Wound Infection / Q000209:etiology; D015996:Survival Rate
chemical_list: D002316:Cardiotonic Agents